Gemcitabine
|
Phase 3 |
Randomized, multicenter international |
160 |
Gemcitabine vs. 5-Flourouracil |
5.65 vs. 4.41 months |
9 vs. 4 weeks |
5.4 % vs. 0 % |
18 % vs. 2 % |
Burris H, et al. [1] |
FOLFIRINOX
|
Phase 2 |
Single arm; multicenter |
47 |
None |
10.2 (8.1–14.4 months) |
8.2 (5.3–11.6 months) |
26 % (13–39 %) |
43 % |
Conroy et al. [5] |
Phase 3 |
Phases 2–3, randomized, placebo-controlled, multicenter, international. |
342 |
FOLFIRINOX vs. Gemcitabine |
11.1 vs. 6.8 months |
6.4 vs. 3.3 months |
31.6 % vs. 9.4 % |
48 % vs. 20 % |
Conroy et al. [3] |
Nab-Paclitaxel
|
Phase 2 |
Single arm, open-label, multicenter, phase I/II |
67 |
None |
12.2 (8.9–18 months) |
7.9 (5.8–11 months) |
46 % (N/A) |
48 % |
Von Hoff et al. [21] |
Phase 3 |
Randomized phase III, multicenter |
861 |
Gemcitabine ± Nab-Paclitaxel or Placebo |
8.5 vs. 6.7 months |
5.5 vs. 3.7 months |
23 % vs. 7 % |
35 % vs. 22 % |
Von Hoff et al. [22] |
Erlotinib
|
Phase 3 |
Randomized, double-blinded, placebo-controlled, international |
569 |
Gemcitabine ± erlotinib or Placebo |
6.24 vs. 5.91 months |
3.75 vs. 3.55 months |
8.6 % vs. 8.0 % |
23 % vs. 17 % |
Moore M, et al. [25] |